首页> 外文期刊>Prescrire international >erenumab (aimovig0) for the prevention of migraine attacks-Notable decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects
【24h】

erenumab (aimovig0) for the prevention of migraine attacks-Notable decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects

机译:Erenumab(Aimovig0)用于预防偏头痛攻击 - 一些患者的攻击频率下降,但在心血管作用上不确定性

获取原文
获取原文并翻译 | 示例
           

摘要

The first-choice drug for the prevention of migraine attacks is oral propranolol, taken daily. Amitriptyline and valproic acid are other options, although valproic acid must not be used in women who are or could become pregnant. Erenumab is a monoclonal antibody that binds to the CGRP receptor. CGRP is a neuro-peptide that has vasodilating and gastrointestinal effects and modulates nociceptive signalling. Erenumab has been authorised in the European Union forthe prevention of migraine attacks in patients who experience attacks on more than 4 days a month. It is administered monthly by subcutaneous injection. Erenumab has not been compared in head-to-head trials with other drugs used to prevent migraine attacks.
机译:预防偏头痛攻击的首选药物是口服丙醇,每日服用。 阿米替林和丙戊酸是其他选择,尽管不得用于或可能会怀孕的女性不得使用丙络酸。 Erenumab是一种与CGRP受体结合的单克隆抗体。 CGRP是一种神经肽,其具有血管沉积和胃肠道效应并调节伤害性信号传导。 Erenumab已在欧洲联盟授权,预防患者每月超过4天的患者遭受患者的偏头痛攻击。 它通过皮下注射每月施用。 Erenumab尚未与用于预防偏头痛攻击的其他药物的头部对头试验。

著录项

  • 来源
    《Prescrire international》 |2019年第207期|共5页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号